Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 11, 2023 - Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer Read
- Nov. 6, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Nov. 2, 2023 - Puma Biotechnology Reports Third Quarter 2023 Financial Results Read
- Oct. 19, 2023 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results Read
- Oct. 14, 2023 - Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting Read
- Oct. 4, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Sept. 21, 2023 - Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer Read
- Aug. 31, 2023 - Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference Read
- Aug. 8, 2023 - Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer Read
- Aug. 3, 2023 - Puma Biotechnology Reports Second Quarter Financial Results Read
- July 20, 2023 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results Read
- June 6, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 4, 2023 - Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting Read
- May 5, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- May 4, 2023 - Puma Biotechnology Reports First Quarter Financial Results Read
- Apr. 20, 2023 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results Read
- Apr. 11, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- March 14, 2023 - Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology Read
- March 3, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- March 2, 2023 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read
- Feb. 28, 2023 - Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference Read
- Feb. 16, 2023 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results Read
- Feb. 7, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Feb. 1, 2023 - Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation Read
- Jan. 12, 2023 - Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference Read
- Jan. 11, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Jan. 9, 2023 - Puma Biotechnology Releases Updated Corporate Presentation Read